Business
SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery
SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery.
About this update from Sohm, Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery\r\n \r\n \r\n\r\n\r\nSOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery\r\n\r\n\r\n\r\n\r\n\r\nCHINO HILLS, CALIFORNIA / ACCESS Newswire / November 6, 2025 / SOHM, Inc. (OTCID:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, a leader in Gene Editing and Cell Engineering is pleased to announced the release of a technical white paper describing ABBIE, a Cas9-guided integrase platform that enables donor-DNA integration without double-strand breaks or viral vectors. Using ABBIE, the team established SKOV3-GYS1, an ovarian cancer cell line with stable overexpression of glycogen synthase 1 (GYS1) to support drug-discovery applications focused on glycogen metabolism.\r\n Highlights from the white paper\r\n \r\n Non-viral, DSB-free integration: ABBIE employs a dCas9-integrase fusion to guide targeted, donor-DNA integration while avoiding double-strand breaks and viral delivery.\r\n Functional overexpression achieved: In ABBIE-engineered cells, GYS1 protein levels were ~3× those of parental SKOV3 cells, and GYS1 catalytic activity exceeded 5× parental levels.\r\n Genomic characterization: Following selection, bulk populations exhibited stable donor integration. Whole-genome sequencing of the highest-expressing clone revealed a single integration event at an intergenic locus.\r\n Targeting note & ongoing work: While ABBIE is guide-directed, the exact insertion coordinates can diverge from the canonical CRISPR-Cas9 target. Ongoing studies are refining target-selection rules and determinants of integration site choice to further improve precision and reproducibility.\r\n \r\n Research and development significance\r\n GYS1 plays a central role in glycogen metabolism and has been implicated in tumor survival under stress conditions. The SKOV3-GYS1 line offers a robust in-vitro platform for mechanistic studies and for screening GYS1-targeting small molecules and other metabolic modulators. More broadly, ABBIE's non-viral, DSB-free approach may help expand knock-in strategies for cell-engineering and model...